Table 1 Correlation between IDO1 expression and clinicopathological features of 97 DLBCL patients.

From: IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma

  

IDO1

  

Characteristics

Cases, n

Lower, n

Higher, n

χ2

P-value

Sex

     

 Male

49

39

10

2.719

0.099

 Female

48

31

17

  

Age

     

 ≤60

63

48

15

1.450

0.229

 >60

34

22

12

  

Stage

     

 I–II

39

33

6

5.033

0.025

 III–IV

58

37

21

  

B symptoms

     

 No

51

39

12

0.993

0.319

 Yes

46

31

15

  

LDH

     

 Normal

59

45

14

1.264

0.261

 Elevated

38

25

13

  

IPI risk group

     

 0–2

70

55

15

5.138

0.023

 3–5

27

15

12

  

No. of extranodal sites

     

 0–1

84

61

23

0.064

0.800

 ≥2

13

9

4

  

subtypes of DLBCL

     

 GCB

15

10

5

0.189

0.664

 Non-GCB

30

18

12

  
  1. DLBCL diffuse large B-cell lymphoma, IDO1 indoleamine 2,3-dioxygenase 1, IPI international prognostic index, LDH lactate dehydrogenase, GCB germinal center B-cell, non-GCB non-germinal center B cell. Statistical analysis was analyzed with a two-sided χ2 test.
Back to article page